DIABETES CIES SEARCH ENGINE [SELECTED WEBSITES]

Friday, October 19, 2007

Lilly and MacroGenics, Licensing and Collaboration Agreement

10/18/2007 – Eli Lilly and Company (NYSE:LLY) and MacroGenics, Inc. announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases. As part of the deal, Lilly will acquire the exclusive rights to the molecule. Teplizumab is currently being studied in the PROTÉGÉ trial, a global pivotal Phase II/III clinical trial for individuals with recent-onset type 1 diabetes*... MacroGenics' Press Release - Lilly's Press Release -

Flamel Technologies, Positive Results of a Phase I Trial

October 18, 2007 - Flamel Technologies (NASDAQ:FLML) announced positive preliminary Phase I data from a trial comparing the safety, tolerability, and long-acting activity of FT-105 versus Lantus , an approved basal insulin. FT-105 is a long-acting recombinant insulin formulation that uses a new microparticulate adaptation of Flamel's proprietary Medusa® nanoparticle delivery system... Flamel Technologies' Press Release -

Thursday, October 18, 2007

Generex Biotechnology, Contract Research Organization to Manage Global Phase III Trials For Generex Oral-lyn

Oct. 16, 2007 - Generex Biotechnology Corporation (NasdaqCM:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that it has entered into a number of key service agreements for its global Phase III trials for Generex Oral-lyn, its proprietary oral insulin spray product... Generex Biotechnology's Press Release -

DARA BioSciences and Bayer Pharmaceuticals, Exclusive License Agreement

October 17, 2007 - DARA BioSciences, Inc. and Bayer Pharmaceuticals Corporation (BPC), a U.S. subsidiary of Bayer HealthCare AG signed a license agreement granting DARA BioSciences exclusive worldwide rights to a series of patents and compounds for the treatment of metabolic diseases, in particular type 2 diabetes and dyslipidemia. Lead compounds are in later preclinical development... DARA BioSciences' Press Release -

Merck , Supplemental New Drug Applications for JANUVIA

Oct. 17, 2007 - Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for JANUVIA™ (sitagliptin), the only DPP-4 inhibitor available in the United States for the treatment of type 2 diabetes. JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. JANUVIA has not been studied in combination with insulin.... Merck's Press Release -

Wednesday, October 17, 2007

Johnson & Johnson, Global Diabetes Institute

October 16, 2007– Johnson & Johnson (NYSE: JNJ) announced the establishment of the Johnson & Johnson Diabetes Institute (JJDI) to transform diabetes care by providing comprehensive training on the latest practice standards, new diabetes tools and technologies and reimbursement solutions to physicians, nurses, physician assistants and diabetes educators around the globe... Johnson & Johnson's Press Release -

Exelixis, Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy

Oct. 16, 2007 - Exelixis, Inc. (Nasdaq: EXEL) announced that a recently completed phase 2 trial of XL784 did not meet its primary endpoint of reducing proteinuria compared with placebo in patients with proteinuria associated with diabetic nephropathy... Exelixis' Press Release -

Hollis-Eden Pharmaceuticals, Phase I/II Clinical Trial with TRIOLEX(TM) (HE3286) in Obese, Insulin Resistant Volunteers

Oct. 16, 2007--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, announced that it is commencing this week a two-stage Phase I/II clinical trial with its oral drug candidate TRIOLEX(TM) (HE3286) in obese, insulin resistant volunteers. TRIOLEX represents a novel class of insulin sensitizers that the Company believes acts by modulating the anti-inflammatory pathway NF-kappaB... Hollis-Eden Pharmaceuticals' Press Release -

Wednesday, October 10, 2007

Living Cell Technologies, Positive Preliminary Data From DiabeCell® Phase I/IIa Trial in Type I Diabetes

October 9, 2007 - Living Cell Technologies Limited (ASX: LCT) released positive preliminary results for its Phase I/IIa clinical trial of the company's proprietary DiabeCell® porcine for the treatment of type 1 diabetes. The clinical trial is being conducted in six type 1 (insulin-dependent) diabetic patients... Living Cell Technologies' Press Release -

Isis, $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007

Calif., Oct 09, 2007 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that it has received a $1.25 million milestone payment in the form of equity securities in iCo Therapeutics. The milestone was related to the initiation of Phase 1 clinical trials of iCo-007, a drug licensed to iCo by Isis in 2005 for the treatment of various eye diseases, including diabetic macular edema...
Isis' Press Release - iCo's Press Release -

Tuesday, October 9, 2007

Johnson & Johnson Pharmaceutical R & D, Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections

October 8, 2007 – Johnson & Johnson Pharmaceutical Research & Development, L.L.C., announced results from a Phase III trial that showed that investigational antibiotic ceftobiprole was found to clinically cure 86% of patients with diabetic foot infections -- including some infections that were caused by methicillin-resistant Staphylococcus aureus (MRSA)... Johnson & Johnson's Press Release -